<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548964</url>
  </required_header>
  <id_info>
    <org_study_id>06-1225 (002)</org_study_id>
    <nct_id>NCT00548964</nct_id>
  </id_info>
  <brief_title>Continuation Ketamine in Major Depression</brief_title>
  <official_title>Continuation Intravenous Ketamine in Major Depressive Disorder - Modification: Lithium for Relapse Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James Murrough</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of&#xD;
      ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a&#xD;
      relapse-prevention strategy for patients with treatment-resistant depression (TRD) who&#xD;
      respond to an initial series of ketamine infusions. Ketamine is a Food and Drug&#xD;
      Administration approved anesthetic (a drug used to produce loss of consciousness before and&#xD;
      during surgery). Ketamine is not approved for the treatment of major depressive disorder and&#xD;
      is considered experimental in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>one week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systematic Assessment for Treatment Emergent Events (SAFT)</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Ketamine + Lithium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive the study drug, IV ketamine, open-label</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants receive the study drug, IV ketamine, open-label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium</intervention_name>
    <description>600-900mg of Li carbonate</description>
    <arm_group_label>Ketamine + Lithium</arm_group_label>
    <other_name>Lithium Carbonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.5mg/kg of ketamine</description>
    <arm_group_label>Ketamine + Lithium</arm_group_label>
    <arm_group_label>Ketamine + Placebo</arm_group_label>
    <other_name>Intravenous ketamine hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, 21-80 years of age;&#xD;
&#xD;
          -  Female individuals who are not of childbearing potential (i.e., surgically sterile,&#xD;
             postmenopausal for at least one year) or using a medically accepted reliable means of&#xD;
             contraception. Women using oral contraceptive medication for birth control must also&#xD;
             be using a barrier contraceptive. Women of childbearing potential must also have a&#xD;
             negative serum B-HCG at screening and at pre-infusion;&#xD;
&#xD;
          -  Participants must fulfill DSM-IV criteria for Major Depression without psychotic&#xD;
             features, based on clinical assessment by a study psychiatrist and confirmed by a&#xD;
             structured diagnostic interview, the Structured Clinical Interview for DSM-IV TR Axis&#xD;
             I Disorders, Patient Edition (SCID-P);&#xD;
&#xD;
          -  Participants must have a history of at least one previous episode of depression prior&#xD;
             to the current episode (recurrent MDD) or have chronic MDD (of at least two years'&#xD;
             duration);&#xD;
&#xD;
          -  Participants have not responded to two or more adequate trials of an antidepressant as&#xD;
             determined by Antidepressant Treatment History Form (ATHF) criteria (score &gt;=3);&#xD;
&#xD;
          -  Participant scores on the IDS-C30 must be greater than or equal to 32;&#xD;
&#xD;
          -  Current major depressive episode is of at least 4 weeks duration;&#xD;
&#xD;
          -  Each participant must have a level of understanding sufficient to agree to all tests&#xD;
             and examinations required by the protocol and must sign an informed consent document;&#xD;
&#xD;
          -  Each participant must be able to identify a family member, physician, or friend who&#xD;
             will participate in the Treatment Contract.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lifetime history of psychotic features, diagnosis of schizophrenia or any other&#xD;
             psychotic disorder, or diagnosis of bipolar disorder;&#xD;
&#xD;
          -  Lifetime histories of autism, mental retardation, pervasive developmental disorders,&#xD;
             or Tourette's syndrome;&#xD;
&#xD;
          -  Current diagnosis of OCD or eating disorder (bulimia nervosa or anorexia nervosa);&#xD;
&#xD;
          -  Subjects with DSM-IV drug or alcohol abuse/dependence within the preceding 2 years;&#xD;
&#xD;
          -  Patients with schizotypal or antisocial personality disorder, or any clinically&#xD;
             significant axis II disorder that would, in the investigator's judgment, preclude safe&#xD;
             study participation;&#xD;
&#xD;
          -  Patients judged clinically to be at serious and imminent suicidal or homicidal risk;&#xD;
&#xD;
          -  Women who are either pregnant or nursing;&#xD;
&#xD;
          -  Serious, unstable medical illnesses including hepatic, renal impairment,&#xD;
             gastroenterologic (including gastro-esophageal reflux disease), respiratory (including&#xD;
             obstructive sleep apnea, or history of difficulty with airway management during&#xD;
             previous anesthetics), cardiovascular (including ischemic heart disease and&#xD;
             uncontrolled hypertension), endocrinologic, neurologic (including history of severe&#xD;
             head injury), immunologic, or hematologic disease;&#xD;
&#xD;
          -  Clinically significant abnormal findings of laboratory parameters, physical&#xD;
             examination, or ECG;&#xD;
&#xD;
          -  Patients who have a positive urine toxicology for illicit substances at screening and&#xD;
             within 24 hours of the infusion;&#xD;
&#xD;
          -  Patients with one or more seizures without a clear and resolved etiology;&#xD;
&#xD;
          -  Treatment with an irreversible MAOI or any other psychotropic medication within 2&#xD;
             weeks prior to randomization (with the exception of a stable dose of&#xD;
             non-benzodiazepines hypnotics);&#xD;
&#xD;
          -  Treatment with fluoxetine within 4 weeks prior to randomization;&#xD;
&#xD;
          -  Previous recreational use of PCP or ketamine;&#xD;
&#xD;
          -  Hypertension (systolic BP &gt;160 mm Hg or diastolic BP &gt;90 mm Hg) not controlled by&#xD;
             diuretic or beta-blocker therapy alone or in combination;&#xD;
&#xD;
          -  A blood pressure reading over 160/90 or two separate readings over 140/90 at screening&#xD;
             or baseline visits;&#xD;
&#xD;
          -  Renal impairment, as reflected by a BUN &gt; 20 mg/dL and/or creatinin clearance of &gt;1.3&#xD;
             mg/dL;&#xD;
&#xD;
          -  Thyroid impairment, as reflected by a TSH &gt; 4.2 mU/L;&#xD;
&#xD;
          -  Cardiac disease, as reflected by an EKG that is abnormal and of concern for cardiac&#xD;
             disease;&#xD;
&#xD;
          -  Any anticipated change in medications that could affect fluid or salt balance,&#xD;
             including the following antihypertensive agents: ACE inhibitor, loop diuretics,&#xD;
             calcium channel blockers, thiazide diuretics, angiotensin II receptor blockers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James W Murrough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64.</citation>
    <PMID>16894061</PMID>
  </reference>
  <reference>
    <citation>Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4.</citation>
    <PMID>10686270</PMID>
  </reference>
  <reference>
    <citation>Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15;74(4):250-6. doi: 10.1016/j.biopsych.2012.06.022. Epub 2012 Jul 27.</citation>
    <PMID>22840761</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>October 24, 2007</study_first_submitted>
  <study_first_submitted_qc>October 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2007</study_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>James Murrough</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>glutamate</keyword>
  <keyword>N-methyl-D-aspartate</keyword>
  <keyword>treatment resistant</keyword>
  <keyword>major depressive disorder</keyword>
  <keyword>lithium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

